| 11:00-11:10 | Break |
SESSION 2—OPEN
QUESTIONS ON STATEMENT OF TASK
| 11:10-11:30 | Project Timeline and Statement of Task Sponsor Representative Introductions Jim Riviere, Committee Chair |
| 11:30-12:15 | Questions to Sponsor |
|
Mary Lou Valdez, Associate Commissioner for International Programs, FDA |
|
|
Kate Bond, Associate Director for Technical Cooperation/Capacity-Building, FDA |
|
| 12:15 | Lunch |
SESSION 3—OPEN
THE FDA PERSPECTIVE
Objective: To learn about the FDA’s current capacity and its international work.
| 12:45 | Welcome the Public and Introduce Commissioner Hamburg Jim Riviere, Committee Chair |
| 12:45-1:05 | Keynote Address: Why is this study important to the FDA? Margaret Hamburg, Commissioner, FDA |
| 1:05-1:25 | Questions |
| 1:25-2:30 | What is the capacity of the FDA Centers? What are the key issues they face in international work? |
|
Deb Autor, Director, FDA Center for Drug Evaluation and Research |
|
|
Karen Midthun, Director, FDA Center for Biologics Evaluation and Research |
|
|
Lillian Gill, Senior Associate Director, FDA Center for Devices and Radiological Health |
|
|
Don Kraemer, Acting Deputy Director for Operations, FDA Center for Food Safety and Applied Nutrition |